Isohemagglutinin Titer, DTH Skin Test Reactivity, and Ig Levels Before and After Gene Therapy
| . | . | Before . | After . |
|---|---|---|---|
| Isohemagglutinin titer | (IgG) | <2 | 16 |
| DTH skin test (mm) | PPD* | 8 × 7 | 12 × 10 |
| Candida | 3 × 3 | 18 × 9 | |
| Tetanus | N.D. | 6 × 5 | |
| Igs | IgG | 720 | 811 |
| IgA | 20 | 53 | |
| IgM | 84 | 128 |
| . | . | Before . | After . |
|---|---|---|---|
| Isohemagglutinin titer | (IgG) | <2 | 16 |
| DTH skin test (mm) | PPD* | 8 × 7 | 12 × 10 |
| Candida | 3 × 3 | 18 × 9 | |
| Tetanus | N.D. | 6 × 5 | |
| Igs | IgG | 720 | 811 |
| IgA | 20 | 53 | |
| IgM | 84 | 128 |
Isohemagglutinin titer and DTH skin tests were tested using standard protocols before gene therapy (before) and at 11 months after the beginning of gene therapy (after) while on PEG-ADA. The patient serum Ig levels were measured just before the Ig replacement on protocol day −60 (before) and 478 (after). The patient received the last Ig replacement at protocol day 348.
The patient had been immunized with BCG at 5 months of age.